Alembic Pharmaceuticals Limited — Investor Meet, 11-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alembic Pharmaceuticals reported Q2 FY26 revenue up 16% YoY to INR 1,910 Cr, with EBITDA climbing 32% to INR 503 Cr (26% margin). Profit after tax grew 30% to INR 185 Cr. Half-year revenue increased 13% to INR 3,621 Cr. India business grew 5%, driven by women's health and animal health. International sales jumped, with ROW up 31% and US up 21% from new launches like Entresto. The company entered the US branded market with Pivya (UTI drug), expecting initial costs but long-term gains. Management projects EBITDA margins to improve towards 18-19% in coming years as new facility utilization picks up. The sentiment is confident on strategic growth areas.